Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas

[1]  C. Amos,et al.  Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations , 2014, Clinical chemistry and laboratory medicine.

[2]  Rashmi Kanagal-Shamanna,et al.  Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics , 2014, Modern Pathology.

[3]  C. Lau,et al.  ERBB4 mutation analysis: emerging molecular target for melanoma treatment. , 2014, Methods in molecular biology.

[4]  Ju-Han Lee,et al.  Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. , 2013, Journal of gastrointestinal and liver diseases : JGLD.

[5]  M. Fassan,et al.  Molecular Typing of Lung Adenocarcinoma on Cytological Samples Using a Multigene Next Generation Sequencing Panel , 2013, PloS one.

[6]  Volker Endris,et al.  Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing. , 2013, The Journal of molecular diagnostics : JMD.

[7]  Roopma Wadhwa,et al.  Gastric cancer—molecular and clinical dimensions , 2013, Nature Reviews Clinical Oncology.

[8]  Ulrich Lehmann,et al.  Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. , 2013, Blood.

[9]  H. Jin,et al.  Helicobacter pylori infection and esophageal cancer risk: an updated meta-analysis. , 2013, World journal of gastroenterology.

[10]  Rashmi Kanagal-Shamanna,et al.  Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.

[11]  Somak Roy,et al.  Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. , 2013, The Journal of clinical endocrinology and metabolism.

[12]  Chandra Sekhar Pedamallu,et al.  Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. , 2013, Cancer research.

[13]  Alexander D. MacKerell,et al.  Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies , 2013, Molecular Cancer Therapeutics.

[14]  N. Hu,et al.  Comparison of Global Gene Expression of Gastric Cardia and Noncardia Cancers from a High-Risk Population in China , 2013, PloS one.

[15]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[16]  M. Santoro,et al.  Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. , 2013, The Journal of clinical endocrinology and metabolism.

[17]  P. Bonate,et al.  Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer , 2013, PloS one.

[18]  J. Leamon,et al.  Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. , 2013, The Journal of molecular diagnostics : JMD.

[19]  Ashish Choudhary,et al.  Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens. , 2013, The Journal of molecular diagnostics : JMD.

[20]  C. la Vecchia,et al.  A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. McKenna,et al.  Exome and whole genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity , 2013, Nature Genetics.

[22]  H. Greulich,et al.  Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment , 2013, Front. Oncol..

[23]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[24]  J. Lee,et al.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. , 2013, Cancer research.

[25]  Minoru Kanehisa,et al.  Molecular network analysis of diseases and drugs in KEGG. , 2013, Methods in molecular biology.

[26]  T. Vaughan,et al.  Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. , 2013, Seminars in radiation oncology.

[27]  M. Fassan,et al.  High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers , 2013, Gastric Cancer.

[28]  J. Berlin,et al.  A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer , 2012, Clinical Cancer Research.

[29]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[30]  Brion W. Murray,et al.  Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors , 2012, Proceedings of the National Academy of Sciences.

[31]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[32]  C. Ong,et al.  Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma. , 2012, Cancer discovery.

[33]  T. Clackson,et al.  Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models , 2012, Molecular Cancer Therapeutics.

[34]  S. Marsal,et al.  Synovial lymphoid neogenesis is associated with IL-23 expression and disease activity in rheumatoid arthritis , 2011, Journal of Translational Medicine.

[35]  Joel S Parker,et al.  Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine , 2011, Journal of Translational Medicine.

[36]  T. Clackson,et al.  Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies , 2011, Molecular Cancer Therapeutics.

[37]  Xianghong Zhang,et al.  Differences of immunophenotypic markers and signaling molecules between adenocarcinomas of gastric cardia and distal stomach. , 2011, Human pathology.

[38]  Laura H. Tang,et al.  Molecular Classification of Gastric Cancer: A New Paradigm , 2011, Clinical Cancer Research.

[39]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[40]  H. Mashimo,et al.  Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System , 2011, Modern Pathology.

[41]  N. Meropol,et al.  In vitro migration of cytotoxic T lymphocyte derived from a colon carcinoma patient is dependent on CCL2 and CCR2 , 2011, Journal of Translational Medicine.

[42]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[43]  K. McColl,et al.  Aetiology and classification of adenocarcinoma of the gastro-oesophageal junction/cardia , 2010, Gut.

[44]  A. Jimeno,et al.  KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. , 2010, The Journal of molecular diagnostics : JMD.

[45]  Richard Simon,et al.  Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. , 2010, Personalized medicine.

[46]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[47]  C. Abnet,et al.  Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort , 2009, Gut.

[48]  F. Islami,et al.  Helicobacter pylori and Esophageal Cancer Risk: A Meta-analysis , 2008, Cancer Prevention Research.

[49]  Y. Chung,et al.  Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers , 2008, Clinical Cancer Research.

[50]  R. Malekzadeh,et al.  Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer , 2007, Gut.

[51]  S. Vollset,et al.  Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status , 2007, Gut.

[52]  M. Kusano,et al.  Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach , 2007, British Journal of Cancer.

[53]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[54]  R. Odze.  Pathology of the gastroesophageal junction. , 2005, Seminars in diagnostic pathology.

[55]  T. Naoe,et al.  Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis , 2005, Leukemia.

[56]  H. Mitsuya,et al.  A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia , 2005, Leukemia.

[57]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[58]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[59]  E. İskender,et al.  Hypermethylation of tumor suppressor genes (p16INK4A, p14ARF and APC) in adenocarcinomas of the upper gastrointestinal tract , 2004, International journal of cancer.

[60]  Thierry Soussi,et al.  Assessing TP53 status in human tumours to evaluate clinical outcome , 2001, Nature Reviews Cancer.

[61]  J. Peters,et al.  Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. , 2000, Annals of surgery.

[62]  M. Mayo,et al.  Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia , 2000, Gut.

[63]  R. Hamelin,et al.  p53 abnormalities in adenocarcinoma of the gastric cardia and antrum. , 1999, Molecular pathology : MP.

[64]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[65]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[66]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .